Leonhardt Ventures Donates to Roy Greenberg, M.D. Memorial and Kids Trust Fund

January 14th, 2014 – Santa Monica, California – Leonhardt Ventures announced today that it is donating ownership interests of its AortaCell spin out innovation and company to two Roy Greenberg, M.D. Memorial Funds.

0003025360-01i-1_20131211Dr. Roy Greenberg — our friend, collaborative scientist and one of the Cleveland Clinic’s most prolific innovators — died December 7, 2013  after a battle with cancer, he was 49. Known as a pioneer in the field of treating complex aortic disease and he held more than 50 related patents.  He worked closely with Howard Leonhardt and the entire Leonhardt Ventures team over the years in advancing numerous innovations.  “Roy and I are about the same age and we both emerged at the same time in the early innovation years of endovascular stent graft development for aortic aneurysm repair in the mid 1990’s.  He was one of our clinical investigators that truly embraced research and development and was a valuable contributor to improvements that have led to saving thousands of lives.”  Stated Howard Leonhardt, Founder & Chairman of Leonhardt Ventures and AortaCell.   “Roy and I discussed the future of minimally invasive repair of aortic aneurysms utilizing non-invasive wireless electrical energy pulses that recruit stem cells to the weakened wall and then convert them to smooth muscle non-invasively.  He was a strong early believer in the innovations being pioneered by our AortaCell research team and wanted to be actively involved before he became ill.  He thought the technology may be an ideal choice for small aneurysms in particular to catch them and repair them before they become prone to rupture.”  Leonhardt further stated.

Leonhardt Ventures is granting 4% AortaCell seed stage equity divided 2% and 2% to two memorial funds on Dr. Roy Greenberg’s behalf:

1.Dr. Roy Greenberg Memorial Fund for Innovation and International Scholarship in the Heart and Vascular Institute of the Cleveland Clinic. Please consider a gift yourself which can be sent to Cleveland Clinic Foundation, PO Box 931517, Cleveland OH 44193-1655, or online at clevelandclinic.org/giving.

2.  A trust fund for his kids.

In 2012, the Clinic awarded Dr. Greenberg its Sones Innovation Award, which recognizes an individual’s efforts in advancing medical innovation.

Click here > http://www.youtube.com/watch?v=5qByqW3aaLI to watch a video about Dr. Greenberg’s innovations.

February of 2007 Leonhardt founded company Bioheart, Inc. provided a $100,000 un-restricted research gift to the Ohio Cell Therapy Network based on the recommendation of Cleveland Clinic, Ohio State University and Case Western research collaborators which included Dr. Roy Greenberg, Dr. Marc Penn, Dr. Stephen Ellis, Dr. Patrick Whitlow, Dr. Dean Kereiakes and Dr. William Abraham. http://business.highbeam.com/1816/article-1G1-159878680/bioheart-inc-provides-unrestricted-research-grant-ohio

About Leonhardt Ventures:  Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions.  The Leonhardt team pioneered cardiovascular balloon catheters in the 80’s, stent grafts and percutaneous heart valves in the 90’s, stem cell therapies and cardiovascular genetic tests in the 2000s and electrical energy stem cell therapy devices, biological pacemakers and implantable pumps in the 2010’s

AortaCell unit of STEMERGY a Leonhardt Ventures Co. – Stemergy is developing and is early-stage testing a lineup of non-invasive stem cell therapy directing devices – wherever signal is pointed stem cells are recruited and with a flip of a switch those recruited cells can be differentiated into the target organ tissue.  AortaCell is designed to recruit repairative stem cells via a homing signal (SDF-1) released via the application of focally pointed electrically energy pulses delivered via a non-invasive device.  Once a critical mass of cells are recruited to the weakened wall the polarity of the signal is reversed the voltage drops and a differentiation signal is delivered designed to create new smooth muscle and thus repairing the aortic aneurysm without intervention.

Web sites:  www.leonhardtventures.com, www.bioleonhardt.com, www.myostimpacers.com, www.calxstars.com, www.bioheartinc.com, ;

Cal-X Stars – www.calxstars.com
Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc. is the only 5 year business accelerator focused on cardiovascular and social good impact innovations.

Contact:  Howard Leonhardt, Leonhardt Ventures,  1531 6th Street, Unit 401, Santa Monica, California, 90401, Office direct 310 310 2534, Email hleonhardt@aol.com

Comments are closed.